









Markets
/
Stocks
/
nasdaq-lrmr
/

Larimar Therapeutics Inc

LRMR

3.370USD

+0.300+9.77%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

288.44MMarket Cap

LossP/E TTM



Larimar Therapeutics Inc

3.370

+0.300+9.77%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Larimar Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Larimar Therapeutics Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 110 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 15.20.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Larimar Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

110 / 392

Overall Ranking

240 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Larimar Therapeutics Inc Highlights

StrengthsRisks

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -1.72, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 86.18M shares, increasing 3.33% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 3.09K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.23.

Analyst Rating

Based on 11 analysts

Strong Buy

Current Rating

15.200

Target Price

+395.11%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Larimar Therapeutics Inc is 5.45, ranking 363 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.45

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.42

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Larimar Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Larimar Therapeutics Inc is 6.05, ranking 339 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.72, which is -33.77% below the recent high of -1.14 and -816.62% above the recent low of -15.78.

Score

Industry at a Glance

Previous score

6.05

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 110/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Larimar Therapeutics Inc is 9.27, ranking 8 out of 392 in the Biotechnology & Medical Research industry. The average price target is 18.00, with a high of 26.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

9.27

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 11 analysts

Strong Buy

Current Rating

15.200

Target Price

+395.11%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Larimar Therapeutics Inc

LRMR

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Larimar Therapeutics Inc is 6.97, ranking 127 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.74 and the support level at 3.03, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.25

Change

0.72

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.032

Sell

RSI(14)

46.780

Neutral

STOCH(KDJ)(9,3,3)

29.894

Neutral

ATR(14)

0.236

High Vlolatility

CCI(14)

-70.951

Neutral

Williams %R

54.930

Neutral

TRIX(12,20)

-0.155

Sell

StochRSI(14)

83.571

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

3.336

Buy

MA10

3.474

Sell

MA20

3.406

Sell

MA50

3.578

Sell

MA100

3.811

Sell

MA200

3.442

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Larimar Therapeutics Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 103.72%, representing a quarter-over-quarter increase of 19.24%. The largest institutional shareholder is The Vanguard, holding a total of 3.05M shares, representing 3.67% of shares outstanding, with 5.84% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Deerfield Management Company, L.P.

30.61M

RA Capital Management, LP

6.05M

Blue Owl Capital Holdings LP

5.85M

+18.77%

Millennium Management LLC

4.90M

+33.97%

Opaleye Management Inc.

3.72M

-9.47%

RTW Investments L.P.

3.13M

The Vanguard Group, Inc.

Star Investors

3.09M

+44.15%

BlackRock Institutional Trust Company, N.A.

2.97M

+7.93%

Adage Capital Management, L.P.

1.90M

Alyeska Investment Group, L.P.

1.89M

-9.09%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Larimar Therapeutics Inc. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 1.02. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.